Eli Lilly agreed to acquire exclusive worldwide rights to MeiraGTx’s AAV‑AIPL1 gene therapy for Leber congenital amaurosis 4 (LCA4), paying $75 million up front and up to $400 million in milestones. MeiraGTx reported Phase I results in The Lancet showing that infants treated early regained measurable vision, and Lilly said it will pursue regulatory filings in the US and UK. The deal expands Lilly’s push into genetic medicines and retinal disease.